PDSB Stock — PDS Biotechnology Corporation: Cash, EV, Pipeline

Share price

$0.81

Market cap

$58.4M

Cash

$5.6M

Enterprise value

$52.8M

Balance sheet

Cash	$5.6M
Debt	$0.0M
Net cash	$5.6M
Enterprise value	$52.8M
Basic shares	55.9M shares
Fully diluted shares	64.8M shares
Fully diluted market cap	$52.5M
Cash per share	$0.10

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading PDSB daily closes…

Loading price history…

Pipeline assets

PDS0301

Phase 2 · Active Modality: tumor-targeted IL-12 immunocytokine (subcutaneous injection)

Aliases formerly PDS01ADC

Target IL-12

Partnerships n/a (NCI running Phase 2 trials)

Indications

Metastatic colorectal cancer (with hepatic artery infusion pump + systemic therapy) (Phase 2)
HPV-positive malignancies (with PDS0101 + bintrafusp alfa) (Phase 2)
Localized cancer (with stereotactic body radiation therapy) (Phase 2)
Metastatic castration-sensitive and castration-resistant prostate cancer (with docetaxel) (Phase 1)

Status note Lead program following August 2026 strategic refocus.

PDS0101

Phase 3 · Terminated Modality: Versamune T-cell activating immunotherapy

Target HPV16

Partnerships n/a (seeking strategic partnerships or other externally funded opportunities for continued development)

Indications

HPV16-positive recurrent/metastatic head and neck cancer (Phase 3)

Status note VERSATILE-003 Phase 3 discontinued in August 2026; company ceased further internal investment. Enrolled patients remain on trial and continue treatment.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

No specialist-fund holders in 13F data for this company.

PDSB — PDS Biotechnology Corporation

Balance sheet

Price history

Pipeline assets